Valérie Olié

Learn More
Venous thrombosis is a common disease that frequently recurs. Recurrence can be prevented by anticoagulants, albeit at the cost of bleeding. Thus, assessment of the risk of recurrence is important to balance the risks and benefits of anticoagulation treatment. Many clinical and laboratory risk factors for recurrent venous thrombosis have been established.(More)
OBJECTIVE Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women. Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, the impact of the route of estrogen administration and concomitant progestogens is not fully established. METHODS AND RESULTS We used data from the E3N French(More)
AIMS The objectives of this study were to describe annual trends in patients hospitalized for heart failure (HF) and HF-associated mortality rates in France between 2000 and 2012. METHODS AND RESULTS Hospital discharge data were extracted from the French National Hospitalization Database (PMSI). Mortality data were obtained from the French National(More)
BACKGROUND Men have higher risk of recurrent venous thromboembolism (VTE) than women but this sex difference remains unexplained. In addition, whether men and women share same risk factors for recurrent VTE is unclear. METHODS In a prospective cohort study, 583 patients (234 men and 349 women) aged 18 to 90, with a first idiopathic VTE, were followed for(More)
PURPOSE OF REVIEW Venous thromboembolism (VTE) is a main harmful effect of oral estrogen therapy among postmenopausal women. Transdermal estrogens may be safer but early results need to be confirmed. This review provides a summary of the most recent findings regarding the VTE risk among oral versus transdermal estrogens users. RECENT FINDINGS Since 2008,(More)
OBJECTIVES The route of estrogen administration is an important determinant of the risk of the first venous thromboembolism (VTE) event in postmenopausal women using hormone therapy (HT). However, the impact of transdermal estrogens on VTE recurrence risk has not been investigated. The aim of our study was to assess the impact of HT by route of estrogen(More)
BACKGROUND Circannual variations in the incidence and mortality of pulmonary embolism (PE) have been previously described although conflicting observations have been reported. However, the association between age and seasonal variations of incidence and mortality rates is not established. This nationwide study aimed to assess the seasonal pattern in(More)
BACKGROUND A dramatic reduction in mortality from myocardial infarction (MI) has been observed in France as in other western countries. The dynamics of this decline are likely to have differed according to age and sex. Our study sought to clarify the contributions of age, period and birth-cohort effects on post-MI mortality in France between 1975 and 2010(More)
OBJECTIVE Although the route of estrogen administration is known to be an important determinant of the thrombotic risk among postmenopausal women using hormone therapy, recent data have shown that norpregnane derivatives but not micronized progesterone increase venous thromboembolism risk among transdermal estrogens users. However, the differential effects(More)
INTRODUCTION Hormone therapy (HT) is the most effective treatment to counteract menopauserelated symptoms. Because venous thromboembolism (VTE) is the main harmful effect of HT among young postmenopausal women, reducing VTE risk appears to be a relevant strategy to improve the benefit/risk profile of HT among postmenopausal women. METHODS This article is(More)